Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan + raltitrexed chemoradiotherapy with or without bevacizumab for recurrent colorectal cancer
ChiCTR2000039535Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan, raltitrexed and bevacizumab in colorectal cancer (CRC) (2 arms), sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Objective response rate. Started Jan 2021; status: recruiting.
02
Drugs
irinotecanraltitrexedbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2000039535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039535.